Anti-Sm: its predictive value in systemic lupus erythematosus

Clin Rheumatol. 1993 Sep;12(3):350-3. doi: 10.1007/BF02231577.


The clinical manifestations of 131 rheumatic disease patients with anti-Sm antibody were studied. A variety of standard tests was utilized in the study, namely, the FANA test with mouse kidney as substrate for the assay of ANA, the Crithidia test for anti-double stranded DNA (anti-dsDNA) and double immunodiffusion for detecting antibodies to extractable nuclear antigens. The patients were grouped according to the presence of anti-Sm alone, or anti-Sm with some other antibodies. There were 17 with anti-Sm alone; 55 with anti-Sm+anti-RNP; 15 with anti-Sm+anti-dsDNA; and 44 with anti-Sm+anti-RNP. The result of our study showed that although anti-Sm could be found in other diseases, it was exclusively detected in SLE only if anti-dsDNA was also present. Further, the SLE patients with anti-Sm alone had more frequent central nervous system manifestations than other groups of patients. The renal manifestation was observed more frequently in the group of SLE patients with anti-Sm+anti-dsDNA (92.9%). Among other major manifestations, haematologic involvement had a tendency to be less common in the group of patients with anti-Sm alone. The study concludes that the presence of anti-Sm antibody may be of some value to predict the clinical outcome.

MeSH terms

  • Antibodies, Antinuclear / analysis*
  • Autoantigens / immunology*
  • DNA / immunology
  • Humans
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / immunology*
  • Predictive Value of Tests
  • Rheumatic Diseases / diagnosis
  • Rheumatic Diseases / immunology
  • Ribonucleoproteins, Small Nuclear*
  • Skin Diseases / etiology
  • snRNP Core Proteins


  • Antibodies, Antinuclear
  • Autoantigens
  • Ribonucleoproteins, Small Nuclear
  • snRNP Core Proteins
  • DNA